Immatics (IMTX) Debt to Equity (2020 - 2022)

Immatics recorded quarterly Debt to Equity of $0.18 in Q3 2022, up 56.45% quarter-over-quarter from $0.11 in Q2 2022, and down 76.33% year-over-year from $0.75 in Q3 2021.

Immatics' Debt to Equity history runs 3 years deep, the most recent figure standing at $0.18 for Q3 2022.

  • In Q3 2022, Debt to Equity fell 76.33% year-over-year to $0.18; the TTM figure through Sep 2022 stood at $0.18 (down 76.33% YoY), while the FY2021 annual figure was $1.16, up 3597.17% from the prior year.
  • Debt to Equity came in at $0.18 for Q3 2022 at Immatics, up from $0.11 in the prior quarter.
  • In the past five years, Debt to Equity ranged from a high of $1.16 in Q4 2021 to a low of $0.03 in Q4 2020.
  • A 3-year average of $0.37 and a median of $0.21 in 2021 frame the typical range for Debt to Equity.
  • Across the five-year window, Debt to Equity jumped 3597.17% in 2021 and tumbled 76.33% in 2022, its largest moves.
  • Immatics' Debt to Equity stood at $0.03 in 2020, then surged by 3597.17% to $1.16 in 2021, then plunged by 84.73% to $0.18 in 2022.
  • According to Business Quant data, Debt to Equity over the past three periods registered $0.18, $0.11, and $0.1 for Q3 2022, Q2 2022, and Q1 2022 respectively.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Debt/Equity (Qtr)
1 Quantum Biopharma 1,216,509.61 Bn 1,216,509.61 Bn - -
2 Alterity Therapeutics 764,224.41 Bn 764,224.38 Bn - -
3 Legend Biotech 2,716.00 Bn 2,715.71 Bn 242.10 Mn -
4 Nanobiotix 2,248.83 Bn 2,248.77 Bn - -
5 Akari Therapeutics 1,951.18 Bn 1,951.17 Bn - -
6 Vertex Pharmaceuticals 113.69 Bn 106.44 Bn 2.59 Bn -
7 Evaxion A 64.16 Bn 64.14 Bn - -
8 Regeneron Pharmaceuticals 63.94 Bn 55.18 Bn 3.31 Bn 0.06
9 Alnylam Pharmaceuticals 40.13 Bn 37.12 Bn 959.66 Mn -
10 Immatics 1.80 Bn 1.80 Bn - -

Historic Data

Download Data 🔒
DateValue
Sep 30, 2022 0.18
Jun 30, 2022 0.11
Mar 31, 2022 0.10
Dec 31, 2021 1.16
Sep 30, 2021 0.75
Jun 30, 2021 0.37
Mar 31, 2021 0.24
Dec 31, 2020 0.03